| FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer T Conroy, F Desseigne, M Ychou, O Bouché, R Guimbaud, Y Bécouarn, ... New England journal of medicine 364 (19), 1817-1825, 2011 | 8170 | 2011 |
| Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations LV Sequist, JCH Yang, N Yamamoto, K O'Byrne, V Hirsh, T Mok, ... Journal of clinical oncology 31 (27), 3327-3334, 2013 | 3769 | 2013 |
| Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised … JCH Yang, YL Wu, M Schuler, M Sebastian, S Popat, N Yamamoto, ... The lancet oncology 16 (2), 141-151, 2015 | 1780 | 2015 |
| Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial J Bennouna, J Sastre, D Arnold, P Österlund, R Greil, E Van Cutsem, ... The lancet oncology 14 (1), 29-37, 2013 | 1361 | 2013 |
| First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open … L Paz-Ares, TE Ciuleanu, M Cobo, M Schenker, B Zurawski, J Menezes, ... The Lancet Oncology 22 (2), 198-211, 2021 | 1064 | 2021 |
| Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer E Van Cutsem, WL Vervenne, J Bennouna, Y Humblet, S Gill, ... Journal of clinical oncology 27 (13), 2231-2237, 2009 | 803 | 2009 |
| Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer T Kojima, MA Shah, K Muro, E Francois, A Adenis, CH Hsu, T Doi, ... Journal of Clinical Oncology 38 (35), 4138-4148, 2020 | 785 | 2020 |
| T-cell–inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 … PA Ott, YJ Bang, SA Piha-Paul, ARA Razak, J Bennouna, JC Soria, ... Journal of Clinical Oncology 37 (4), 318-327, 2019 | 782 | 2019 |
| Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial E Quoix, G Zalcman, JP Oster, V Westeel, E Pichon, A Lavolé, J Dauba, ... The Lancet 378 (9796), 1079-1088, 2011 | 684 | 2011 |
| Randomized trial comparing a web-mediated follow-up with routine surveillance in lung cancer patients F Denis, C Lethrosne, N Pourel, O Molinier, Y Pointreau, J Domont, ... JNCI: Journal of the National Cancer Institute 109 (9), djx029, 2017 | 469 | 2017 |
| Two-year survival comparing web-based symptom monitoring vs routine surveillance following treatment for lung cancer F Denis, E Basch, AL Septans, J Bennouna, T Urban, AC Dueck, ... Jama 321 (3), 306-307, 2019 | 461 | 2019 |
| Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study HL Kindler, T Ioka, DJ Richel, J Bennouna, R Létourneau, T Okusaka, ... The lancet oncology 12 (3), 256-262, 2011 | 454 | 2011 |
| Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small … G Robinet, P Thomas, JL Breton, H Lena, S Gouva, G Dabouis, ... Annals of oncology 12 (1), 59-67, 2001 | 336 | 2001 |
| Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies HC Chung, SA Piha-Paul, J Lopez-Martin, JHM Schellens, S Kao, ... Journal of Thoracic Oncology 15 (4), 618-627, 2020 | 327 | 2020 |
| Safety and antitumor activity of the anti–programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma T Doi, SA Piha-Paul, SI Jalal, S Saraf, J Lunceford, M Koshiji, J Bennouna Journal of Clinical Oncology 36 (1), 61-67, 2018 | 301 | 2018 |
| Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma J Bennouna, E Bompas, EM Neidhardt, F Rolland, I Philip, C Galéa, ... Cancer immunology, immunotherapy 57, 1599-1609, 2008 | 290 | 2008 |
| Vγ9Vδ2 T cell response to colon carcinoma cells M Corvaisier, A Moreau-Aubry, E Diez, J Bennouna, JF Mosnier, E Scotet, ... The Journal of Immunology 175 (8), 5481-5488, 2005 | 290 | 2005 |
| Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and … B Melichar, A Adenis, AC Lockhart, J Bennouna, EC Dees, O Kayaleh, ... The Lancet Oncology 16 (4), 395-405, 2015 | 286 | 2015 |
| Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal PA Ott, SA Piha-Paul, P Munster, MJ Pishvaian, EMJ Van Brummelen, ... Annals of Oncology 28 (5), 1036-1041, 2017 | 266 | 2017 |
| LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung … JCH Yang, MH Schuler, N Yamamoto, KJ O'Byrne, V Hirsh, T Mok, ... Journal of Clinical Oncology 30 (18_suppl), LBA7500-LBA7500, 2012 | 264 | 2012 |
